NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy of 3′-Deoxy-3′-[18F]fluorothymidine (FLT) as a Marker of Proliferation in Patients with Recurrent Gliomas: Preliminary Efficacy Studies

[1] Grierson JR(2004)Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography Nucl Med Biol 31 829-837

[2] Schwartz JL(2008)Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology Neuro Oncol 10 361-367

[3] Muzi M(2007)Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81-83

[4] Jordan R(2008)NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies Mol Imaging Biol 10 271-280

[5] Krohn KA(2006)Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas J Nucl Med 47 1612-1621

[6] Brandes AA(2004)Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury AJNR Am J Neuroradiol 25 201-209

[7] Tosoni A(1994)Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET AJR Am J Roentgenol 163 1459-1465

[8] Spagnolli F(1992)Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET Radiographics 12 269-279

[9] Chamberlain MC(2006)Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors RoFo 178 627-633

[10] Glantz MJ(1988)PET of malignant cerebral tumors after interstitial brachytherapy J Neurosurg 69 830-838

[1] Grierson JR(2004)Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography Nucl Med Biol 31 829-837

[2] Schwartz JL(2008)Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology Neuro Oncol 10 361-367

[3] Muzi M(2007)Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81-83

[4] Jordan R(2008)NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies Mol Imaging Biol 10 271-280

[5] Krohn KA(2006)Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas J Nucl Med 47 1612-1621

[6] Brandes AA(2004)Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury AJNR Am J Neuroradiol 25 201-209

[7] Tosoni A(1994)Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET AJR Am J Roentgenol 163 1459-1465

[8] Spagnolli F(1992)Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET Radiographics 12 269-279

[9] Chamberlain MC(2006)Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors RoFo 178 627-633

[10] Glantz MJ(1988)PET of malignant cerebral tumors after interstitial brachytherapy J Neurosurg 69 830-838